Adenosine receptors as therapeutic targets (original) (raw)

• Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K. N. & Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527–552 (2001). A publication on AR nomenclature, structure, function and regulation by members of NC-IUPHAR subcommittee.
  CAS PubMed Google Scholar
• Linden, J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67, 1385–1387 (2005). Summarizes four modes of adenosine's tissue protective action.
  Article CAS PubMed Google Scholar
• McGaraughty, S., Cowart, M., Jarvis, M. F. & Berman, R. F. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr. Top. Med. Chem. 5, 43–58 (2005).
  Article CAS PubMed Google Scholar
• Zimmermann, H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 362, 299–309 (2000).
  Article CAS PubMed Google Scholar
• Pascual, O. et al. Astrocytic purinergic signalling coordinates synaptic networks. Science 310, 113–116 (2005).
  Article CAS PubMed Google Scholar
• Parkinson, F. E., Xiong, W. & Zamzow, C. R. Astrocytes and neurons: different roles in regulating adenosine levels. Neurol. Res. 27, 153–160 (2005).
  Article CAS PubMed Google Scholar
• Gao, Z. G., Kim, S. K., IJzerman, A. P. & Jacobson, K. A. Allosteric modulation of the adenosine family of receptors. Mini Rev. Med. Chem. 5, 545–553 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• van Calker, D., Muller, M. & Hamprecht, B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33, 999–1005 (1979).
  Article CAS PubMed Google Scholar
• Londos, C., Cooper, D. M. & Wolff, J. Subclasses of external adenosine receptors. Proc. Natl Acad. Sci. USA 77, 2551–2554 (1980).
  Article CAS PubMed Google Scholar
• Tawfik, H. E., Schnermann, J., Oldenburg, P. J. & Mustafa, S. J. Role of A1 adenosine receptors in the regulation of vascular tone. Am. J. Physiol. Heart Circ. Physiol. 288, H1411–H1416 (2005).
  Article CAS PubMed Google Scholar
• Rogel, A., Bromberg, Y., Sperling, O. & Zoref-Shani, E. Phospholipase C is involved in the adenosine-activated signal transduction pathway conferring protection against iodoacetic acid-induced injury in primary rat neuronal cultures. Neurosci. Lett. 373, 218–221 (2005).
  Article CAS PubMed Google Scholar
• Belardinelli, L., Shryock, J. C., Song, Y., Wang, D. & Srinivas, M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J. 9, 359–365 (1995).
  Article CAS PubMed Google Scholar
• Reid, E. A. et al. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signalling. Am. J. Physiol. Heart Circ. Physiol. 288, H2253–H2259 (2005).
  Article CAS PubMed Google Scholar
• Kull, B., Svenningsson, P. & Fredholm, B. B. Adenosine A2A receptors are colocalized with and activate Golf in rat striatum. Mol. Pharmacol. 58, 771–777 (2000).
  Article CAS PubMed Google Scholar
• Fresco, P., Diniz, C. & Goncalves, J. Facilitation of noradrenaline release by activation of adenosine A2A receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery. Cardiovasc. Res. 63, 739–746 (2004).
  Article CAS PubMed Google Scholar
• Offermanns, S. & Simon, M. I. Gα 15 and Gα 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270, 15175–15180 (1995).
  Article CAS PubMed Google Scholar
• Daly, J. W., Butts-Lamb, P. & Padgett, W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 3, 69–80 (1983).
  Article CAS PubMed Google Scholar
• Brackett, L. E. & Daly, J. W. Functional characterization of the A2B adenosine receptor in NIH 3T3 fibroblasts. Biochem. Pharmacol. 47, 801–814 (1994).
  Article CAS PubMed Google Scholar
• Peakman, M. C. & Hill, S. J. Adenosine A2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. Br. J. Pharmacol. 111, 191–198 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Feoktistov, I. & Biaggioni, I. Adenosine A2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J. Clin. Invest. 96, 1979–1986 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, Z., Chen, T., Weber, M. J. & Linden, J. A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. Cross-talk between cyclic AMP and protein kinase C pathways. J. Biol. Chem. 274, 5972–5980 (1999).
  Article CAS PubMed Google Scholar
• Linden, J., Thai, T., Figler, H., Jin, X. & Robeva, A. S. Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56, 705–713 (1999).
  CAS PubMed Google Scholar
• Donoso, M. V., Lopez, R., Miranda, R., Briones, R. & Huidobro-Toro, J. P. A2B adenosine receptor mediates human chorionic vasoconstriction and signals through the arachidonic acid cascade. Am. J. Physiol. Heart Circ. Physiol. 288, H2439–H2449 (2005).
  Article CAS PubMed Google Scholar
• Zhou, Q. Y. et al. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl Acad. Sci. USA 89, 7432–7436 (1992).
  Article CAS PubMed Google Scholar
• Abbracchio, M. P. et al. G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol. Pharmacol. 48, 1038–1045 (1995).
  CAS PubMed Google Scholar
• Shneyvays, V. et al. Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am. J. Physiol. Heart Circ. Physiol. 288, H2792–H2801 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Englert, M., Quitterer, U. & Klotz, K. N. Effector coupling of stably transfected human A3 adenosine receptors in CHO cells. Biochem. Pharmacol. 64, 61–65 (2002).
  Article CAS PubMed Google Scholar
• Fossetta, J. et al. Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol. Pharmacol. 63, 342–350 (2003).
  Article CAS PubMed Google Scholar
• Shneyvays, V., Zinman, T. & Shainberg, A. Analysis of calcium responses mediated by the A3 adenosine receptor in cultured newborn rat cardiac myocytes. Cell Calcium 36, 387–396 (2004).
  Article CAS PubMed Google Scholar
• Tracey, W. R., Magee, W., Masamune, H., Oleynek, J. J. & Hill, R. J. Selective activation of adenosine A3 receptors with _N_6-(3-chlorobenzyl)-5′-_N_-methylcarbox-amidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation. Cardiovasc. Res. 40, 138–145 (1998).
  Article CAS PubMed Google Scholar
• Mozzicato, S., Joshi, B. V., Jacobson, K. A. & Liang, B. T. Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J. 18, 406–408 (2004).
  Article CAS PubMed Google Scholar
• Fishman, P. et al. Evidence for involvement of Wnt signalling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21, 4060–4064 (2002).
  Article CAS PubMed Google Scholar
• Schulte, G. & Fredholm, B. B. Signalling pathway from the human adenosine A3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol. Pharmacol. 62, 1137–1146 (2002).
  Article CAS PubMed Google Scholar
• Schulte, G. & Fredholm, B. B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 15, 813–827 (2003). Reports that each of the four ARs can activate one or more of the MAPKs by substantially different mechanisms.
  Article CAS PubMed Google Scholar
• Merighi, S. et al. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase (PI3K)/AKT-dependent inhibition of the extracellular signal-regulated kinase (ERK)1/2 phosphorylation in A375 human melanoma cells. J. Biol. Chem. 280, 19516–19526 (2005).
  Article CAS PubMed Google Scholar
• Olah, M. E. & Stiles, G. L. The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther. 85, 55–75 (2000).
  Article CAS PubMed Google Scholar
• Yan, L., Burbiel, J. C., Maass, A. & Müller, C. E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs 8, 537–576 (2003).
  Article CAS Google Scholar
• Kim, S. K. et al. Modelling the adenosine receptors: Comparison of binding domains of A2A agonist and antagonist. J. Med. Chem. 46, 4847–4859 (2003).
  Article CAS PubMed Google Scholar
• Tchilibon, S. et al. (N)-Methanocarba-2,_N_6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J. Med. Chem. 48, 1745–1758 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Moro, S., Gao, Z. G., Jacobson, K. A. & Spalluto, G. Progress in pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 26, 131–159 (2006). Summary of the most recent progress in developing new therapeutic AR antagonists.
  Article CAS PubMed Google Scholar
• Moro, S., Bacillieri, M., Cacciari, B. & Spalluto, G. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A3 adenosine receptor antagonists. J. Med. Chem. 48, 5698–5704 (2005).
  Article CAS PubMed Google Scholar
• Gao, Z. G. et al. Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 45, 4471–4484 (2002).
  Article CAS PubMed Google Scholar
• Gao, Z. G., Blaustein, J., Gross, A. S., Melman, N. & Jacobson, K. A. _N_6–Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors, Biochem. Pharmacol. 65, 1675–1684 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, P. L., Wysocki, R. J. Jr, Barrett, R. J., May, J. M. & Linden, J. Characterization of 8-(_N_-methylisopropyl)amino-_N_6-(5′-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J. Pharmacol. Exp. Ther. 276, 490–499 (1996).
  CAS PubMed Google Scholar
• Rieger, J. M., Brown, M. L., Sullivan, G. W., Linden, J. & MacDonald, T. L. Design, synthesis, and evaluation of novel adenosine A2A receptor agonists. J. Med. Chem. 44, 531–539 (2001).
  Article CAS PubMed Google Scholar
• Bridges, A. J. et al. _N_6-[2-(3, 5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor. J. Med. Chem. 31, 1282–1285 (1988).
  Article CAS PubMed Google Scholar
• Palmer, T. M., Poucher, S. M., Jacobson, K. A. & Stiles, G. L. 125I-4-(2-[7-Amino-2-{furyl}{1,2,4}tri-azolo{2,3-a}{1,3,5}triazin-5-ylaminoethyl)phenol (125I-ZM241385), a high affinity antagonist radioligand selective for the A2A adenosine receptor. _Mol. Pharmacol._ **48**, 970–974 (1996).
  Google Scholar
• Baraldi, P. G. et al. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]1, 2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. J. Med. Chem. 41, 2126–2133 (1998).
  Article CAS PubMed Google Scholar
• Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
  CAS PubMed PubMed Central Google Scholar
• Kase, H. et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61, S97–S100 (2003).
  Article CAS PubMed Google Scholar
• Volpini, R., Costanzi, S., Vittori, S., Cristalli, G. & Klotz, K. N. Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem. 3, 427–443 (2003).
  Article CAS PubMed Google Scholar
• Beukers, M. W. et al. New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamido-adenosine. J. Med. Chem. 47, 3707–3709 (2004). The first report of non-nucleoside agonists for the human A 2B AR, with one of those compounds showing potency of about 10 nM.
  Article CAS PubMed Google Scholar
• Ji, X., Kim, Y. C., Ahern, D. G., Linden, J. & Jacobson, K. A. [3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem. Pharmacol. 61, 657–663 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Gessi, S. et al. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20. Mol. Pharmacol. 67, 2137–2147 (2005).
  Article CAS PubMed Google Scholar
• Stewart, M. et al. [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem. Pharmacol. 68, 305–312 (2004).
  Article CAS PubMed Google Scholar
• Jacobson, K. A. A3 adenosine receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19, 184–191 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Olah, M. E., Gallo-Rodriguez, C., Jacobson, K. A. & Stiles, G. L. 125I-4-Aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol. Pharmacol. 45, 978–982 (1994).
  CAS PubMed PubMed Central Google Scholar
• Jeong, L. S. et al. _N_6–Substituted D-4′-thioadenosine-5′-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J. Med. Chem. 46, 3775–3777 (2003).
  Article CAS PubMed Google Scholar
• Linden, J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 15, 298–306 (1994).
  Article CAS PubMed Google Scholar
• Yang, H. et al. The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr. Eye Res. 30, 747–754 (2005). Application of the first rationally designed, cross-species, nucleoside antagonist in an animal model for antiglaucoma effects.
  Article CAS PubMed PubMed Central Google Scholar
• Müller, C. E., Diekmann, M., Thorand, M. & Ozola, V. [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors. Bioorg. Med. Chem. Lett. 12, 501–503 (2002).
  Article PubMed Google Scholar
• Perreira, M. et al. 'Reversine' and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 48, 4910–4918 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Zablocki, J. A., Wu, L., Shryock, J. & Belardinelli, L. Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Curr. Top. Med. Chem. 4, 839–854 (2004).
  Article CAS PubMed Google Scholar
• Fraser, H., Gao, Z., Ozeck, M. J. & Belardinelli, L. N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J. Pharmacol. Exp. Ther. 305, 225–231 (2003).
  Article CAS PubMed Google Scholar
• Bayes, M., Rabasseda, X. & Prous, J. R. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 25, 831–855 (2003).
  CAS PubMed Google Scholar
• Ellenbogen, K. A. et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 111, 3202–3208 (2005). Reports that the A 1 AR agonist, Tecadenoson, terminates paroxysmal supraventricular tachycardia without the clinically significant side effects caused by stimulation of other ARs.
  Article CAS PubMed Google Scholar
• Wagner, H. et al. General pharmacology of SDZ WAG-994, a potent selective and orally-active adenosine A1 receptor agonist. Drug Dev. Res. 34, 276–288 (1995).
  Article CAS Google Scholar
• Auchampach, J. A. et al. Selective activation of A3 adenosine receptors with _N_6-(3-iodobenzyl) adenosine-5′-_N_-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ. Res. 80, 800–809 (1997).
  Article CAS PubMed Google Scholar
• Schindler, C. W. et al. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br. J. Pharmacol. 144, 642–650 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Schulte, G. et al. Adenosine A1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia. Acta Physiol. Scand. 182, 133–143 (2004).
  Article CAS PubMed Google Scholar
• Matherne, G. P., Linden, J., Byford, A. M., Gauthier, N. S. & Headrick, J. P. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc. Natl Acad. Sci. USA 94, 6541–6546 (1997).
  Article CAS PubMed Google Scholar
• Gauthier, N. S., Headrick, J. P. & Matherne, G. P. Myocardial function in the working mouse heart overexpressing cardiac A1 adenosine receptors. J. Mol. Cell. Cardiol. 30, 187–193 (1998).
  Article CAS PubMed Google Scholar
• Yang, Z. et al. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 282, H949–H955 (2002).
  Article CAS PubMed Google Scholar
• Headrick, J. P., Gauthier, N. S., Morrison, R. & Matherne, G. P. Cardioprotection by K(ATP) channels in wild-type hearts and hearts overexpressing A1-adenosine receptors. Am. J. Physiol. Heart Circ. Physiol. 279, H1690–H1697 (2000).
  Article CAS PubMed Google Scholar
• Cerniway, R. J., Yang, Z., Jacobson, M. A., Linden, J. & Matherne, G. P. Targeted deletion of A3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 281, H1751–H1758 (2001).
  Article CAS PubMed Google Scholar
• Joosen, M. J., Bueters, T. J. & van Helden, H. P. Cardiovascular effects of the adenosine A1 receptor agonist _N_6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning. Arch. Toxicol. 78, 34–39 (2004).
  Article CAS PubMed Google Scholar
• Reichelt, M. E. et al. Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ. Res. 96, 363–367 (2005).
  Article CAS PubMed Google Scholar
• Tracey, W. R. et al. Novel _N_6-substituted adenosine 5′-_N_-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 285, H2780–H2787 (2003).
  Article CAS PubMed Google Scholar
• Cross, H. R., Murphy, E., Black, R. G., Auchampach, J. & Steenbergen, C. Overexpression of A3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am. J. Physiol. Heart Circ. Physiol. 283, H1562–H1568 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Black, R. G. et al. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ. Res. 91, 165–172 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, Y. et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J. Mol. Cell Cardiol. 33, 825–830 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Harrison, G. J. et al. Effects of A3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc. Res. 53, 147–155 (2002).
  Article CAS PubMed Google Scholar
• Yang, Z. et al. Infarct sparing effect of A2A-adenosine receptor activation is due primarily to its actions on lymphocytes. Circulation 111, 2190–2197 (2005).
  Article CAS PubMed Google Scholar
• Gerlai, R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19, 177–181 (1996).
  Article CAS PubMed Google Scholar
• De Jonge, R., Out, M., Maas, W. J. & De Jong, J. W. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur. J. Pharmacol. 441, 165–172 (2002).
  Article CAS PubMed Google Scholar
• Wang, J. et al. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur. J. Pharmacol. 320, 241–248 (1997).
  Article CAS PubMed Google Scholar
• Shneyvays, V., Mamedova, L., Zinman, T., Jacobson, K. A. & Shainberg, A. Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J. Mol. Cell. Cardiol. 33, 1249–1261 (2001).
  Article CAS PubMed Google Scholar
• Varani, K. et al. Dose and time effects of caffeine intake on human platelet adenosine A2A receptors: functional and biochemical aspects. Circulation 102, 285–289 (2000).
  Article CAS PubMed Google Scholar
• Hendel, R.C. et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J. Am. Coll. Cardiol. 46, 2069–2075 (2005).
  Article CAS PubMed Google Scholar
• Barrett, R. J., Lamson, M. J., Johnson, J. & Smith, W. B. Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J. Nucl. Cardiol. 12, 166–171 (2005).
  Article PubMed Google Scholar
• Rubino, A., Ralevic, V. & Burnstock, G. The P1-purinoceptors that mediate the prejunctional inhibitory effect of adenosine on capsaicin-sensitive nonadrenergic noncholinergic neurotransmission in the rat mesenteric arterial bed are of the A1 subtype. J. Pharmacol. Exp. Ther. 267, 1100–1104 (1993).
  CAS PubMed Google Scholar
• Szentmiklosi, A. J. et al. Adenosine receptors mediate both contractile and relaxant effects of adenosine in main pulmonary artery of guinea pigs. Naunyn. Schmiedebergs Arch. Pharmacol. 351, 417–425 (1995).
  Article CAS Google Scholar
• Eltzschig, H. K. et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signalling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 198, 783–796 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Dubey, R. K., Gillespie, D. G., Shue, H. & Jackson, E. K. A2B receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 35, 267–272 (2000).
  Article CAS PubMed Google Scholar
• Chen, Y. et al. Functional effects of enhancing or silencing adenosine A2B receptors in cardiac fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 287, H2478–H2486 (2004).
  Article CAS PubMed Google Scholar
• Matheson, P. J., Spain, D. A., Harris, P. D., Garrison, R. N. & Wilson, M. A. Glucose and glutamine gavage increase portal vein nitric oxide metabolite levels via adenosine A2B activation. J. Surg. Res. 84, 57–63 (1999).
  Article CAS PubMed Google Scholar
• Feoktistov, I. et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 44, 649–654 (2004). Description of the angiogenic role of the A 2B AR under hypoxic conditions.
  Article CAS PubMed Google Scholar
• Tilley, S. L., Wagoner, V. A., Salvatore, C. A., Jacobson, M. A. & Koller, B. H. Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells. J. Clin. Invest. 105, 361–367 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, Z., Makaritsis, K., Francis, C. E., Gavras, H. & Ravid, K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim. Biophys. Acta 1500, 280–290 (2000).
  Article CAS PubMed Google Scholar
• Talukder, M. A. et al. Targeted deletion of adenosine A3 receptors augments adenosine-induced coronary flow in isolated mouse heart. Am. J. Physiol. Heart Circ. Physiol. 282, H2183–H2189 (2002).
  Article CAS PubMed Google Scholar
• Jones, M. R. et al. A3 adenosine receptor deficiency does not influence atherogenesis. J. Cell Biochem. 92, 1034–1043 (2004).
  Article CAS PubMed Google Scholar
• Solinas, M. et al. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl.) 179, 576–586 (2005).
  Article CAS Google Scholar
• Ledent, C. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 388, 674–678 (1997). The first demonstration of A 2A AR-mediated effects, such as pain, aggregation of platelets, hypertension and caffeine's stimulant effect, by using a receptor-knockout model.
  Article CAS Google Scholar
• Fredholm, B. B., Chen, J. F., Masino, S. A. & Vaugeois, J. M. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 45, 385–412 (2005). A thoughtful overview of the roles of ARs in CNS disorders.
  Article CAS PubMed Google Scholar
• Huang, Z. L. et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nature Neurosci. 8, 858–859 (2005). The authors used both A 1 AR- and A 2A AR-knockout mice to show that the A 2A AR, not the A 1 AR, is crucial in caffeine-induced wakefulness.
  Article CAS PubMed Google Scholar
• Satoh, S., Matsumura, H. & Hayaishi, O. Involvement of adenosine A2A receptor in sleep promotion. Eur. J. Pharmacol. 351, 155–162 (1998).
  Article CAS PubMed Google Scholar
• Maemoto, T. et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J. Pharmacol. Sci. 96, 42–52 (2004).
  Article CAS PubMed Google Scholar
• Sawynok, J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 347, 1–11 (1998).
  Article CAS PubMed Google Scholar
• Johansson, B. et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. USA 98, 9407–9412 (2001). Initial study of A 1 AR-mediated CNS effect by using A 1 AR-knockout mice.
  Article CAS PubMed Google Scholar
• Wu, W. P. et al. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 113, 395–404 (2005).
  Article CAS PubMed Google Scholar
• Gordh, T., Karlsten, R. & Kristensen, J. Intervention with spinal NMDA, adenosine, and NO systems for pain modulation. Ann. Med. 27, 229–234 (1995).
  Article CAS PubMed Google Scholar
• Giffin, N. J. et al. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 23, 287–292 (2003).
  Article CAS PubMed Google Scholar
• Zambrowicz, B. P., Turner, C. A. & Sands, A. T. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr. Opin. Pharmacol. 3, 563–570 (2003).
  Article CAS PubMed Google Scholar
• Li, X., Conklin, D., Pan, H. L. & Eisenach, J. C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J. Pharmacol. Exp. Ther. 305, 950–955 (2003).
  Article CAS PubMed Google Scholar
• Ferre, S., von Euler, G., Johansson, B., Fredholm, B. B. & Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl Acad. Sci. USA 88, 7238–7241 (1991).
  Article CAS PubMed Google Scholar
• Hillion, J. et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091–18097 (2002).
  Article CAS PubMed Google Scholar
• Svenningsson, P., Le Moine, C., Fisone, G. & Fredholm, B. B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355–396 (1999).
  Article CAS PubMed Google Scholar
• Aoyama, S., Kase, H. & Borrelli, E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20, 5848–5852 (2000).
  Article CAS PubMed Google Scholar
• Xu, K., Bastia, E. & Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105, 267–310 (2005).
  Article CAS PubMed Google Scholar
• Ross, G. W. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 2674–2679 (2000).
  Article CAS PubMed Google Scholar
• Ascherio, A. et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50, 56–63 (2001).
  Article CAS PubMed Google Scholar
• Bara-Jimenez, W. et al. Adenosine A2A receptor antagonist treatment of Parkinson's disease. Neurology 61, 293–296 (2003).
  Article CAS PubMed Google Scholar
• Hauser, R. A., Hubble, J. P. & Truong, D. D. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 61, 297–303 (2003).
  Article CAS PubMed Google Scholar
• Weiss, S. M. et al. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61, S101–S106 (2003).
  Article CAS PubMed Google Scholar
• Matasi, J. J. et al. The discovery and synthesis of novel adenosine receptor A2A antagonists. Bioorg. Med. Chem. Lett. 15, 1333–1336 (2005).
  Article CAS PubMed Google Scholar
• Peng, H. et al. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J. Med. Chem. 47, 6218–6229 (2004).
  Article CAS PubMed Google Scholar
• Chen, J. F. et al. A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19, 9192–9200 (1999). Provides a genetic basis for treating PD with A 2A AR antagonists.
  Article CAS PubMed Google Scholar
• Monopoli, A., Lozza, G., Forlani, A., Mattavelli, A. & Ongini, E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9, 3955–3959 (1998).
  Article CAS PubMed Google Scholar
• Blum, D. et al. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23, 5361–5369 (2003).
  Article CAS PubMed Google Scholar
• Yu, L. et al. Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nature Med. 10, 1081–1087 (2004).
  Article CAS PubMed Google Scholar
• Aden, U. et al. Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke 34, 739–744 (2003).
  Article CAS PubMed Google Scholar
• Mayne, M. et al. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49, 727–735 (2001).
  Article CAS PubMed Google Scholar
• Cassada, D. C. et al. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann. Thorac. Surg. 74, 846–849 (2002).
  Article PubMed Google Scholar
• von Lubitz, D. K. J. E. et al. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur. J. Pharmacol. 316, 171–179 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Knutsen, L. J. et al. N-substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects. J. Med. Chem. 42, 3463–3477 (1999).
  Article CAS PubMed Google Scholar
• Olsson, T. et al. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. Eur. J. Neurosci. 20, 1197–1204 (2004).
  Article PubMed Google Scholar
• Turner, C. P. et al. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc. Natl Acad. Sci. USA 100, 11718–11722 (2003).
  Article CAS PubMed Google Scholar
• Stevens, B., Porta, S., Haak, L. L., Gallo, V. & Fields, R. D. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 36, 855–868 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Linden, J. et al. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol. 44, 524–532 (1993).
  CAS PubMed Google Scholar
• Dixon, A. K., Gubitz, A. K., Sirinathsinghji, D. J., Richardson, P. J. & Freeman, T. C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118, 1461–1468 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, Z., Yaar, R., Ladd, D., Cataldo, L. M. & Ravid, K. Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. Microvasc. Res. 63, 61–69 (2002).
  Article CAS PubMed Google Scholar
• Jacobson, K. A. et al. A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 336, 57–60 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• von Lubitz, D. K. J. E., Lin, R. C.-S., Popik, P., Carter, M. F. & Jacobson, K. A. Adenosine A3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263, 59–67 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Porkka-Heiskanen, T. et al. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 276, 1265–1268 (1997). Shows that adenosine is a physiological sleep factor that mediates the somnogenic effects of prior wakefulness.
  Article CAS PubMed PubMed Central Google Scholar
• Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A. & Stenberg, D. Adenosine and sleep. Sleep Med. Rev. 6, 321–332 (2002).
  Article PubMed Google Scholar
• Stenberg, D. et al. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J. Sleep Res. 12, 283–290 (2003).
  Article PubMed Google Scholar
• Urade, Y. et al. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology 61, S94–S96 (2003).
  Article CAS PubMed Google Scholar
• Basheer, R., Strecker, R. E., Thakkar, M. M. & McCarley, R. W. Adenosine and sleep-wake regulation. Prog. Neurobiol. 73, 379–396 (2004).
  Article CAS PubMed Google Scholar
• Yao, L. et al. βγ dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signalling and regulate ethanol consumption. Cell 109, 733–743 (2002).
  Article CAS PubMed Google Scholar
• Mailliard, W. S. & Diamond, I. Recent advances in the neurobiology of alcoholism: the role of adenosine. Pharmacol. Ther. 101, 39–46 (2004).
  Article CAS PubMed Google Scholar
• Bauer, A. et al. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J. Nucl. Med. 46, 450–454 (2005).
  CAS PubMed Google Scholar
• Moresco, R. M. et al. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur. J. Nucl. Med. Mol. Imaging 32, 405–413 (2005).
  Article CAS PubMed Google Scholar
• El Yacoubi, M. et al. Absence of the adenosine A2A receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 40, 424–432 (2001).
  Article CAS PubMed Google Scholar
• Lee, H. T. & Emala, C. W. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors. Am. J. Physiol. Renal Physiol. 278, F380–F387 (2000).
  Article CAS PubMed Google Scholar
• Pingle, S. C. et al. Osmotic diuretics induce adenosine A1 receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis. J. Biol. Chem. 279, 43157–43167 (2004).
  Article CAS PubMed Google Scholar
• Brown, R. et al. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1362–R1367 (2001).
  CAS PubMed Google Scholar
• Sun, D. et al. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine A1 receptors. Proc. Natl Acad. Sci. USA 98, 9983–9988 (2001).
  Article CAS PubMed Google Scholar
• Lee, H. T., Xu, H., Nasr, S. H., Schnermann, J. & Emala, C. W. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am. J. Physiol. Renal Physiol. 286, F298–F306 (2004).
  Article CAS PubMed Google Scholar
• Wilcox, C. S., Welch, W. J., Schreiner, G. F. & Belardinelli, L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J. Am. Soc. Nephrol. 10, 714–720 (1999).
  CAS PubMed Google Scholar
• Gottlieb, S. S. et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105, 1348–1353 (2002).
  Article CAS PubMed Google Scholar
• Auchampach, J. A. et al. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J. Pharmacol. Exp. Ther. 308, 846–856 (2004).
  Article CAS PubMed Google Scholar
• Day, Y. J. et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112, 883–891 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Okusa, M. D. et al. A2A adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am. J. Physiol. Renal Physiol. 279, F809–F818 (2000).
  Article CAS PubMed Google Scholar
• Zannikos, P. N. et al. Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. J. Clin. Pharmacol. 40, 745–751 (2000).
  Article CAS PubMed Google Scholar
• Vitzthum, H., Weiss, B., Bachleitner, W., Kramer, B. K. & Kurtz, A. Gene expression of adenosine receptors along the nephron. Kidney Int. 65, 1180–1190 (2004).
  Article CAS PubMed Google Scholar
• Cooper, J., Hill, S. J. & Alexander, S. P. An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells. Br. J. Pharmacol. 122, 546–550 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Dubey, R. K., Gillespie, D. G., Mi, Z. & Jackson, E. K. Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A2B receptors. Hypertension 46, 628–634 (2005).
  Article CAS PubMed Google Scholar
• Lee, H. T. et al. A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. Am. J. Physiol. Renal Physiol. 284, F267–F273 (2003).
  Article CAS PubMed Google Scholar
• Sun, C. X. et al. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J. Clin. Invest. 115, 35–43 (2005). Uses A 1 AR- and adenosine deaminase-deficient mice to show the occurrence of anti-inflammatory actions of adenosine in the lung, mediated through A 1 ARs, on macrophages.
  Article CAS PubMed PubMed Central Google Scholar
• Holgate, S. T. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br. J. Pharmacol. 145, 1009–1015 (2005). Comprehensive description of the role of the A 2B AR in asthma, which provides a firm basis for developing A 2B AR antagonists as a new therapeutic approach to this disease.
  Article CAS PubMed PubMed Central Google Scholar
• Salvatore, C. A. et al. Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275, 4429–4434 (2000).
  Article CAS PubMed Google Scholar
• Feoktistov, I. & Biaggioni, I. Role of adenosine in asthma. Drug Dev. Res. 39, 333–336 (1996).
  Article CAS PubMed Google Scholar
• Ryzhov, S. et al. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J. Immunol. 172, 7726–7733 (2004).
  Article CAS PubMed Google Scholar
• Auchampach, J. A., Jin, X., Wan, T. C., Caughey, G. H. & Linden, J. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol. Pharmacol. 52, 846–860 (1997).
  Article CAS PubMed Google Scholar
• Press, N. J. et al. A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. Bioorg. Med. Chem. Lett. 15, 3081–3085 (2005).
  Article CAS PubMed Google Scholar
• Fozard, J. R., Ellis, K. M., Villela Dantas, M. F., Tigani, B. & Mazzoni, L. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. 438, 183–188 (2002).
  Article CAS PubMed Google Scholar
• Glaxo Group Ltd: WO9967263, WO9967264, WO9967265 & WO9967266. Selective A2A receptor agonists as inhibitors of cellular activation. Expert Opin. Ther. Pat. 10, 723–728 (2000).
• Rivo, J., Zeira, E., Galun, E. & Matot, I. Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. Am. J. Transplant. 4, 1941–1948 (2004).
  Article CAS PubMed Google Scholar
• Sitkovsky, M. V. et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657–682 (2004). Comprehensive overview of the roles of A 2A ARs in immune response and inflammation-related tissue damage.
  Article CAS PubMed Google Scholar
• Erdmann, A. A. et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2 driven expansion in vivo. Blood 105, 4707–4714 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lappas, C. M., Rieger, J. M. & Linden, J. A2A adenosine receptor induction inhibits IFN- production in murine CD4+ T cells. J. Immunol. 174, 1073–1080 (2005).
  Article CAS PubMed Google Scholar
• Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001). Describes that A 2A ARs are crucially involved in the limitation and termination of inflammation. No other mechanism for inflammation could compensate fully for the loss of A 2A ARs on immune cells.
  Article CAS PubMed Google Scholar
• Kirkpatrick, P. Putting the brake on inflammation. Nature Rev. Drug Disc. 1, 99 (2002).
  Article CAS Google Scholar
• Montesinos, M. C. et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48, 240–247 (2003).
  Article CAS PubMed Google Scholar
• Day, Y. J. et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G285–G293 (2004).
  Article CAS PubMed Google Scholar
• Sullivan, G. W., Fang, G., Linden, J. & Scheld, W. M. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis. 189, 1897–1904 (2004).
  Article CAS PubMed Google Scholar
• Odashima, M. et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129, 26–33 (2005).
  Article CAS PubMed Google Scholar
• Peirce, S. M., Skalak, T. C., Rieger, J. M., Macdonald, T. L. & Linden, J. Selective A2A adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am. J. Physiol. Heart Circ. Physiol. 281, H67–H74 (2001).
  Article CAS PubMed Google Scholar
• Montesinos, M. C. et al. Wound healing is accelerated by agonists of adenosine A2 (Gαs-linked) receptors. J. Exp. Med. 186, 1615–1620 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Ramkumar, V., Stiles, G. L., Beaven, M. A. & Ali, H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268, 16887–16890 (1993).
  CAS PubMed Google Scholar
• Haskó, G. & Cronstein, B. N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25, 33–39 (2004). Summary of adenosine's promotion of a self-limiting, healthy immune response in endothelial cells, neutrophils and mast cells.
  Article CAS PubMed Google Scholar
• Baharav, E. et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32, 469–476 (2005).
  CAS PubMed Google Scholar
• Dong, Q., Ginsberg, H. N. & Erlanger, B. F. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. Diabetes Obes. Metab. 3, 360–366 (2001).
  Article CAS PubMed Google Scholar
• Harada, H. et al. 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J. Med. Chem. 44, 170–179 (2001).
  Article CAS PubMed Google Scholar
• Kohno, Y., Sei, Y., Koshiba, M., Kim, H. O. & Jacobson, K. A. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A3 receptor agonists. Biochem. Biophys. Res. Commun. 219, 904–910 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, S. G. et al. p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem. Pharmacol. 63, 871–880 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, Z., Li, B. S., Day, Y. J. & Linden, J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol. 59, 76–82 (2001).
  Article CAS PubMed Google Scholar
• Neary, J. T., McCarthy, M., Kang, Y. & Zuniga, S. Mitogenic signalling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci. Lett. 242, 159–162 (1998).
  Article CAS PubMed Google Scholar
• Merighi, S. et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermatol. 119, 923–933 (2002).
  Article CAS PubMed Google Scholar
• Fishman, P., Bar-Yehuda, S., Madi, L. & Cohn, I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13, 437–443 (2002).
  Article CAS PubMed Google Scholar
• Madi, L. et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin. Cancer Res. 10, 4472–4479 (2004). Shows that colon and breast carcinoma tissues have higher A 3 AR expression in the tumour versus adjacent non-neoplastic tissue or normal tissue, which provided a basis for the use of A 3 AR agonists in cancer therapy.
  Article CAS PubMed Google Scholar
• Lu, J., Pierron, A. & Ravid, K. An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res. 63, 6413–6423 (2003).
  CAS PubMed Google Scholar
• Avila, M. Y., Stone, R. A. & Civan, M. M. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 43, 3021–3026 (2002).
  PubMed Google Scholar
• Okamura, T. et al. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett. 14, 3775–3779 (2004).
  Article CAS PubMed Google Scholar
• Jacobson, K. A. et al. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides, J. Med. Chem. 44, 4125–4136 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Jacobson, K. A. et al. A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. Chem. Biol. 12, 237–247 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Klotz, K. N. et al. Comparative pharmacology of human adenosine receptor subtypes — characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 357, 1–9 (1998).
  CAS Google Scholar
• Palle, V. P. et al. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg. Med. Chem. Lett. 12, 2935–2939 (2002).
  Article CAS PubMed Google Scholar
• Gao, Z. G. et al. Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J. Med. Chem (in the press).